Galapagos « Terug naar discussie overzicht

Galapagos augustus 2017

3.476 Posts, Pagina: « 1 2 3 4 5 6 ... 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 » | Laatste
MarkvB
2
Ze zouden hier eens waarschuwingen moeten geven voor off-topic gelul, het is hier geen chat room!

(ABM FN-Dow Jones) Op Wall Street zijn dinsdag alle AEX-genoteerde fondsen hoger gesloten in vergelijking tot het slot in Amsterdam. ArcelorMittal was de sterkste stijger.

Aegon (+0,34%)

ArcelorMittal (+1,73%)

ASML (+0,67%)

Galapagos (+0,72%)

ING Groep (+0,81%)

Philips (+0,62%)

RELX (+0,91%)

Royal Dutch Shell (+0,83%)

Unilever (+0,20%)

Op basis van de bovenstaande koersuitslagen zou de AEX index, die sloot op 510,03 punten, zijn geëindigd op 512,43 punten.

Euro/dollar: 1,1966.

Door: ABM Financial News.
info@abmfn.nl
Redactie: +31(0)20 26 28 999

De newsfeed is tenminste 15 minuten vertraagd en is een beperkte weergave van de totale webfeed die ABM Financial News levert.

© Copyright ABM Financial News B.V. All rights reserved. Any redistribution, duplication or archiving prohibited. ABM Financial News B.V. and the provider of this website/application do not warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or delays in the content, or for any actions taken in reliance thereon.
[verwijderd]
0
Je kunt het mij niet kwalijk nemen dat ik de enigmatische berichten hier probeer te ontcijferen, MarkvB. Heb hier in de inrichting verder toch niet zo veel te doen.
harvester
2
galapagos wordt steeds meer genoemd: 3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock
[InvestorPlace]
Tom Taulli
,InvestorPlace•August 29, 2017

Biotech companies are a great source for finding huge gainers. And yes, a clear example of this is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). For the year so far, the shares are up a sizzling 109% to $153, which is an increase of about $18.5 billion in market cap.
VRTX Stock: 3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock
VRTX Stock: 3 Reasons to Be Cautious on Vertex Pharmaceuticals Incorporated (VRTX) Stock

Source: Shutterstock

Founded in the late 1980s, Vertex Pharmaceuticals pioneered groundbreaking therapies for cystic fibrosis. This genetic disease, which has no cure, results in mucus that builds up in a person’s lungs and leads to various medical complications. Unfortunately, life expectancy is 42 to 50 years old.

It was back in early 2012 that Vertex Pharmaceuticals received FDA approval for its drug, Kalydeco. Then a few years later, the company received clearance for Orkambi. The key for both of these treatments is that they target the causes of cystic fibrosis — not the symptoms.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

OK then, for investors, what about the prospects for VRTX stock? Could this company be the next Amgen, Inc. (NASDAQ:AMGN) or Celgene Corporation (NASDAQ:CELG)?

Well, even though Vertex Pharmaceuticals is a standout company and has posted strong growth over the past few years, there should actually be some caution. And here are three reasons why:
VRTX Stock Issue No. 1 — Market

Cystic fibrosis is a rare disease, with about 1,000 new cases reported each year. The global population is about 70,000.

9 Under-the-Radar Retirement Stocks to Buy

In other words, there is an upward limit to the revenue potential. What’s more, given that VRTX has an overwhelming share of the market already, it is likely to get tougher to increase the growth ramp for the long haul.

According to InvestorPlace.com’s Josh Enomoto: “The U.S. market is almost unreasonably small, and the different treatments required necessarily splits the market even further.”

Now, VRTX’s management certainly understands this risk and as a result, has been using its cash flows to fund other drugs that go beyond the core business. But there are some problems — that is, the treatments are still in the early phases and are in highly competitive category.

VRTX Stock Issue No. 2 — Market

Based on data from the Centers for Medicare and Medicaid Services, healthcare costs in the U.S. grew at a 4.8% pace to $3 trillion from 2004 to 2015. The agency also predicts that the rate will increase to 5.6% for the next decade. Just some of the factors for the growth include the aging population, the advances in medical technologies, litigation and the overall lifestyles of Americans.

In light of all these factors, the U.S. government (through Medicare and Medicaid) as well as insurers are looking for ways to deal with the rising costs. Oh, and there are similar approaches in Europe as well (often the policies are even more onerous).

So all of this is certainly worrisome for VRTX stock. Note that the company charges as much as $300,000 per year for its treatments.

All in all, it’s a good bet that — in the coming years — there will be increasing pressures to reduce the pricing.
VRTX Stock Issue No. 3 — Valuation

The valuation on VRTX stock is far from cheap. Consider that the forward price-to-earnings multiple is about 50X.

This Dip in Alibaba Group Holding Ltd (BABA) Stock Is as Good as It Gets

Admittedly, there should be a premium valuation because of the company’s strong growth rate. Yet it is important to keep in mind that there are still plenty of risks, as noted above. Plus, the drug development process can be quite volatile, especially for very complex diseases like cystic fibrosis.

Finally, there is emerging competition in the market. As should be no surprise, a variety of startups, such as Synedgen, are focused on the opportunity, as well as larger players like Galapagos NV (ADR) (NASDAQ:GLPG), which has the backing of AbbVie Inc (NYSE:ABBV).

Tom Taulli runs the InvestorPlace blog IPO Playbook and operates PathwayTax.com, which provides year-round tax services. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities.
[verwijderd]
0
Nog 2 handelsdagen om 23,2 Eur te stijgen en zo de 100eur te halen die er volgens glazenbol Galapump-Diner er zeker zou komen voor het einde van deze maand.
[verwijderd]
0
quote:

SisterFromAnotherMister schreef op 30 augustus 2017 01:11:

Nog 2 handelsdagen om 23,2 Eur te stijgen en zo de 100eur te halen die er volgens glazenbol Galapump-Diner er zeker zou komen voor het einde van deze maand.
Ja, dus?
rakara
0
quote:

MtBaker schreef op 30 augustus 2017 08:22:

effe door die 76,12. wanneer? vandaag wellicht
Komt in orde! ;-)
Sentiment
0
De handel is voorzichtig en rustig.
Je zag die verkoop van 3738 stukken wel de koers naar beneden drukte, maar wel groen bleef. Bemoedigend, maar zegt nog niets
MtBaker
0
Inmiddels boven deopening geweest, volume toename richting 40k of meer. Indicatie denk ik
C200
0
quote:

me_n schreef op 30 augustus 2017 09:51:

Boven de 76,6 gaat het hard omhoog denk ik
Kom maar op dan, 76.62 gezien ;-)
me_n
0
quote:

Daydreamke schreef op 30 augustus 2017 09:53:

Waarom denk je dat?
Afgelopen weken steeds vanaf ongeveer 76,6 terug omlaag gegaan.
KAKO
0
Wellicht is dit al eerder gedeeld (dan mag het verwijderd worden) maar zie hier een vermakelijk fimpje over Galapagos: www.youtube.com/watch?v=31pkxtZopgQ&a...
durobinet
0
Kocht zojuist de call maart '18 85.00 aan €4,15.
Tegen die tijd zal de koers wel op €100 staan, deze maand niet meer!
3.476 Posts, Pagina: « 1 2 3 4 5 6 ... 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 27 mei 2024 14:00
Koers 25,120
Verschil -0,140 (-0,55%)
Hoog 25,280
Laag 25,040
Volume 13.677
Volume gemiddeld 87.020
Volume gisteren 80.198

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront